Cargando…

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging immunotherapeutic approach that is revolutionizing cancer treatment. The impressive clinical results obtained with CAR-T cell therapy in patients with acute lymphoblastic leukemia and lymphoma have fueled the development o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Timmers, Marijke, Roex, Gils, Wang, Yuedi, Campillo-Davo, Diana, Van Tendeloo, Viggo F. I., Chu, Yiwei, Berneman, Zwi N., Luo, Feifei, Van Acker, Heleen H., Anguille, Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646459/ https://www.ncbi.nlm.nih.gov/pubmed/31379824 http://dx.doi.org/10.3389/fimmu.2019.01613

Ejemplares similares

Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
por: Van Acker, Heleen H., et al.
Publicado: (2019)

The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion
por: Van Acker, Heleen H., et al.
Publicado: (2018)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15
por: Van Acker, Heleen H., et al.
Publicado: (2019)

Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
por: Van den Bergh, Johan, et al.
Publicado: (2015)

Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
por: Van Acker, Heleen H., et al.
Publicado: (2016)

Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner
por: Anguille, Sébastien, et al.
Publicado: (2015)

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
por: Van Acker, Heleen H, et al.
Publicado: (2015)

Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
por: Anguille, Sébastien, et al.
Publicado: (2012)

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)

Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC
por: Lion, Eva, et al.
Publicado: (2011)

Correction: Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
por: Anguille, Sébastien, et al.
Publicado: (2014)

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
por: Roex, Gils, et al.
Publicado: (2020)

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
por: Versteven, Maarten, et al.
Publicado: (2018)

In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells
por: van der Heijden, Sanne, et al.
Publicado: (2023)

New Chimeric Antigen Receptor Design for Solid Tumors
por: Wang, Yuedi, et al.
Publicado: (2017)

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells
por: Van Acker, Heleen H., et al.
Publicado: (2017)

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells
por: Willemen, Yannick, et al.
Publicado: (2016)

Regulatory T Cells and Human Disease
por: Cools, Nathalie, et al.
Publicado: (2007)

One-step CRISPR-Cas9-mediated knockout of native TCRαβ genes in human T cells using RNA electroporation
por: Flumens, Donovan, et al.
Publicado: (2023)

Induction of HIV-specific T-cell responses by gag
por: Van Gulck, Ellen, et al.
Publicado: (2006)

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing
por: Campillo-Davo, Diana, et al.
Publicado: (2018)

Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
por: de Bruijn, Sévérine, et al.
Publicado: (2019)

Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
por: Anguille, Sébastien, et al.
Publicado: (2009)

Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8(+ )T cells with peptide-pulsed autologous dendritic cells
por: Cools, Nathalie, et al.
Publicado: (2006)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

CD56 in the Immune System: More Than a Marker for Cytotoxicity?
por: Van Acker, Heleen H., et al.
Publicado: (2017)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma
por: Padda, Jaskamal, et al.
Publicado: (2021)

Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

Interleukin-12p70 Expression by Dendritic Cells of HIV-1-Infected Patients Fails to Stimulate gag-Specific Immune Responses
por: Van Gulck, Ellen, et al.
Publicado: (2012)

Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells
por: Van Craenenbroeck, Amaryllis H., et al.
Publicado: (2015)

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
por: Capsomidis, Anna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_512fnl4u63qu1skps1sdto3991